Perry Kennedy, MD, postdoctoral research fellow, H. Lee Moffitt Cancer Center and Research Institute, discusses RAS as a target as well as the NCI RAS Initiative.
Perry Kennedy, MD
Advertisement
Articles by Perry Kennedy, MD
Advertisement
Latest Updated Articles
Dr. Kennedy on RAS as a TargetPublished: May 9th 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
The OncFive: Top Oncology Articles for the Week of 1/25
4
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
5